Amy Sue Harper, BS, RMA, Honored with Invitation to Join Executive Council for Crohn’s & Colitis Foundation’s Night of Hope Gala

Amy Sue Harper, BS, RMA, founder and CEO of Primera Specialty Infusion, has been invited to join the Executive Council for the Seventh Annual Night of Hope Gala, hosted by the Central Florida Chapter of the Crohn’s & Colitis Foundation (CCF).

The event will take place Saturday, October 18, 2025 at the Margaritaville Resort Orlando, bringing together community leaders, advocates, and supporters to raise funds for critical research and local patient service programs in Orlando and the surrounding Central Florida communities.

“I’m honored to be part of such a meaningful event that not only raises money for groundbreaking research but also directly supports families living with Crohn’s disease and ulcerative colitis,” said Harper. “As someone deeply committed to patient advocacy and access to care, this cause is very close to my heart and aligns perfectly with our mission at Primera Specialty Infusion.”

About the Crohn’s & Colitis Foundation
Founded in 1967, the Crohn’s & Colitis Foundation is the leading nonprofit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life for children and adults affected by these diseases.

About Primera Specialty Infusion
Primera Specialty Infusion, based in Lake Mary, Florida, provides high-quality, patient-centered infusion and wellness therapies, including biologics, IV hydration, nutrients, peptides, and other chronic care treatments. Primera is dedicated to improving patient access to care and delivering personalized treatment in a comfortable, supportive environment.

Why It Matters
More than 10 million people worldwide live with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The Crohn’s & Colitis Foundation invests 80 cents of every dollar raised into research and local programs, providing education, advocacy, and resources for those navigating life with chronic illness. Since its inception, the Foundation has invested over $500 million in research and has played a role in every major scientific breakthrough for Crohn’s and colitis, including the discovery of the first gene for Crohn’s disease.